Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 362708, 8 pages
http://dx.doi.org/10.1155/2014/362708
Research Article

The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis

1Laboratory for Radiobiology and Molecular Genetics, “Vinča” Institute of Nuclear Sciences, University of Belgrade, 11000 Belgrade, Serbia
2Department of Biology and Medical Genetics, School of Medicine, University of Rijeka, 51000 Rijeka, Croatia
3Clinical Institute of Medical Genetics, University Medical Centre, 1000 Ljubljana, Slovenia
4Department of Neurology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina
5Department of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia
6Neurology Clinic, Military Medical Academy, 11000 Belgrade, Serbia
7Department of Neurology, University Medical Centre, 1000 Ljubljana, Slovenia
8Department of Neurology, School of Medicine, University of Tuzla, 75000 Tuzla, Bosnia and Herzegovina
9Postgraduate Studies, School of Medicine, University of Rijeka, 51000 Rijeka, Croatia

Received 4 February 2014; Accepted 31 March 2014; Published 16 April 2014

Academic Editor: Ralf Lichtinghagen

Copyright © 2014 Maja Živković et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Sawcer, G. Hellenthal, M. Pirinen et al., “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis,” Nature, vol. 476, no. 7359, pp. 214–219, 2011. View at Google Scholar
  2. S. E. Baranzini and D. Nickles, “Genetics of multiple sclerosis: swimming in an ocean of data,” Current Opinion in Neurology, vol. 25, no. 3, pp. 239–245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. E. East, D. Baker, G. Pryce, H. R. Lijnen, M. L. Cuzner, and D. Gverić, “A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis,” The American Journal of Pathology, vol. 167, no. 2, pp. 545–554, 2005. View at Google Scholar · View at Scopus
  4. T. Teesalu, A. E. Hinkkanen, and A. Vaheri, “Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice,” The American Journal of Pathology, vol. 159, no. 6, pp. 2227–2237, 2001. View at Google Scholar · View at Scopus
  5. D. Gveric, R. Hanemaaijer, J. Newcombe, N. A. Van Lent, C. F. M. Sier, and M. L. Cuzner, “Plasminogen activators in multiple sclerosis lesions implications for the inflammatory response and axonal damage,” Brain, vol. 124, no. 10, pp. 1978–1988, 2001. View at Google Scholar · View at Scopus
  6. D. Gverić, B. Herrera, A. Petzold, D. A. Lawrence, and M. L. Cuzner, “Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors,” Brain, vol. 126, no. 7, pp. 1590–1598, 2003. View at Google Scholar · View at Scopus
  7. D. Gverić, B. M. Herrera, and M. L. Cuzner, “tPA receptors and the fibrinolytic response in multiple sclerosis lesions,” The American Journal of Pathology, vol. 166, no. 4, pp. 1143–1151, 2005. View at Google Scholar · View at Scopus
  8. E. East, D. Gverić, D. Baker, G. Pryce, H. R. Lijnen, and M. L. Cuzner, “Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation,” Neuropathology and Applied Neurobiology, vol. 34, no. 2, pp. 216–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Jern, P. Ladenvall, U. Wall, and S. Jern, “Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 2, pp. 454–459, 1999. View at Google Scholar · View at Scopus
  10. P. Eriksson, B. Kallin, F. M. Van't Hooft, P. Bavenholm, and A. Hamsten, “Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 6, pp. 1851–1855, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Luomala, I. Elovaara, M. Ukkonen, T. Koivula, and T. Lehtimäki, “Plasminogen activator inhibitor 1 gene and risk of MS in women,” Neurology, vol. 54, no. 9, pp. 1862–1864, 2000. View at Google Scholar · View at Scopus
  12. L. Lovrečić, S. Ristić, N. Starčević-Čizmarević et al., “PAI and TPA gene polymorphisms in multiple sclerosis,” Multiple Sclerosis Journal, vol. 14, no. 2, pp. 243–247, 2008. View at Google Scholar
  13. C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. D. Lublin and S. C. Reingold, “Defining the clinical course of multiple sclerosis: results of an international survey,” Neurology, vol. 46, no. 4, pp. 907–911, 1996. View at Google Scholar · View at Scopus
  15. R. H. Roxburgh, S. R. Seaman, T. Masterman et al., “Multiple sclerosis severity score: using disability and disease duration to rate disease severity,” Neurology, vol. 64, no. 7, pp. 1144–1151, 2005. View at Google Scholar · View at Scopus
  16. J. F. Kurtzke, “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS),” Neurology, vol. 33, no. 11, pp. 1444–1452, 1983. View at Google Scholar · View at Scopus
  17. M. Margaglione, E. Grandone, G. Cappucci et al., “An alternative method for PAI-1 promoter polymorphism (4G/5G) typing,” Thrombosis and haemostasis, vol. 77, no. 3, pp. 605–606, 1997. View at Google Scholar · View at Scopus
  18. Z. Ye, E. H. C. Liu, J. P. T. Higgins et al., “Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls,” The Lancet, vol. 367, no. 9511, pp. 651–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Hultman, A. Tjärnlund-Wolf, J. Odeberg, P. Eriksson, and C. Jern, “Allele-specific transcription of the PAI-1 gene in human astrocytes,” Thrombosis and Haemostasis, vol. 104, no. 5, pp. 998–1008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. L. Haines, M. Ter-Minassian, A. Bazyk et al., “A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group,” Nature Genetics, vol. 13, no. 4, pp. 469–471, 1996. View at Google Scholar
  21. I. Gravanis and S. E. Tsirka, “Tissue plasminogen activator and glial function,” Glia, vol. 49, no. 2, pp. 177–183, 2005. View at Google Scholar
  22. J. Chmielewska, M. Ranby, and B. Wiman, “Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor: evidence for 'second-site' interactions,” Biochemical Journal, vol. 251, no. 2, pp. 327–332, 1988. View at Google Scholar · View at Scopus
  23. S. E. Tsirka, A. D. Rogove, T. H. Bugge, J. L. Degen, and S. Strickland, “An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus,” Journal of Neuroscience, vol. 17, no. 2, pp. 543–552, 1997. View at Google Scholar · View at Scopus
  24. M. Yepes, M. Sandkvist, E. G. Moore, T. H. Bugge, D. K. Strickland, and D. A. Lawrence, “Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein,” Journal of Clinical Investigation, vol. 112, no. 10, pp. 1533–1540, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Nagai, I. Vanlinthout, and D. Collen, “Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models,” Circulation, vol. 100, no. 25, pp. 2541–2546, 1999. View at Google Scholar · View at Scopus
  26. W. Lu, M. Bhasin, and S. E. Tsirka, “Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis,” Journal of Neuroscience, vol. 22, no. 24, pp. 10781–10789, 2002. View at Google Scholar · View at Scopus
  27. A. Reijerkerk, G. Kooij, S. M. A. van der pol et al., “Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier,” Journal of Immunology, vol. 181, no. 5, pp. 3567–3574, 2008. View at Google Scholar · View at Scopus
  28. S. Lemarchant, F. Docagne, E. Emery, D. Vivien, C. Ali, and M. Rubio, “TPA in the injured central nervous system: different scenarios starring the same actor?” Neuropharmacology, vol. 62, no. 2, pp. 749–756, 2012. View at Publisher · View at Google Scholar · View at Scopus